More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/BAY 58-2667 . hydrochloride [646995-35-9]
Chemical Structure
Chemical Structure
Chemical Structure

BAY 58-2667 . hydrochloride [646995-35-9]

Research Use Only
AG-CR1-3509
AdipoGen Life Sciences
Estimated Purity>98% (NMR)
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Molecular Weight565.6 . 36.5 . 9.0
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    BAY 58-2667 . hydrochloride [646995-35-9]
  • Delivery Days Customer
    10
  • Certification
    Research Use Only
  • Estimated Purity
    >98% (NMR)
  • Hazard Information
    Non-hazardous
  • Molecular Formula
    C36H39NO5 . HCl . 0.5H2O
  • Molecular Weight
    565.6 . 36.5 . 9.0
  • Scientific Description
    Chemical. CAS: 646995-35-9. Formula: C36H39NO5 . HCl . 0.5H2O. MW: 565.6 . 36.5 . 9.0. Nitric oxide (NO)- and heme-independent soluble guanylyl cyclase activator. Shows potent cardiovascular effects. Improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Exhibits potent vasodilator and antiplatelet activity. Anti-aggregating agent. - Nitric oxide (NO)- and heme-independent soluble guanylyl cyclase activator. Shows potent cardiovascular effects. Improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Exhibits potent vasodilator and antiplatelet activity. Anti-aggregating agent.
  • SMILES
    Cl.OC(=O)CCCCN(CCC1=C(OCC2=CC=C(CCC3=CC=CC=C3)C=C2)C=CC=C1)CC1=CC=C(C=C1)C(O)=O
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle: J.P. Stasch, et al.; Br. J. Pharmacol. 136, 773 (2002)
  • Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase: P. Schmidt, et al.; Eur. J. Pharmacol. 468, 167 (2003)
  • Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease: G. Boerrigter & JC. Burnett Jr.; Cardiovasc. Drug Rev. 25, 30 (2007) (Review)
  • Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers: R. Frey, et al.; J. Clin. Pharmacol. 48, 1400 (2008)
  • BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts: T. Krieg, et al.; Eur. Heart J. 30, 1607 (2009)
  • Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure: H. Lapp, et al.; Circulation 119, 2781 (2009)
  • Role of guanylate cyclase modulators in decompensated heart failure: V. Mitrovic, et al.; Heart Fail. Rev. 14, 309 (2009) (Review)
  • Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure: J. Tamargo, et al.; Curr. Opin. Investig. Drugs 11, 1039 (2010)
  • Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase: S. Roger, et al.; Vascul. Pharmacol. 53, 281 (2010)
  • Transgenic mice for real time visualization of cGMP in intact adult cardiomyocytes: K. Götz, et al.; Circ. Res. 114, 1235 (2014)